NEWS BRIEF · Research journal
ZEUS has spoken: lessons for IL-6 inhibition and the road ahead
From the report
Nature Cardiovascular Research, Published online: 13 November 2026; doi:10.1038/s44161-026-00930-3Interleukin-6 (IL-6) signaling has been implicated in atherosclerotic cardiovascular disease (ASCVD), yet neutralizing IL-6 with ziltivekimab did not cut cardiovascular events in patients with ASCVD and chronic kidney disease in the ZEUS clinical trial. I explore possible explanations and implications for immune-targeting strategies in ASCVD.